Bio Medica Laboratories IPO

About Bio Medica Laboratories IPO

The Bio Medica Laboratories IPO opens on Thursday, May 21, 2026 and closes on Monday, May 25, 2026. The allotment of shares will take place on Tuesday, May 26, 2026. The credit of shares to the demat account will take place on Wednesday, May 27, 2026. The initiation of refunds will take place on Wednesday, May 27, 2026. The listing of shares will take place on Friday, May 29, 2026.

The offer consists of both a fresh issue and an offer for sale component. The fresh issue will include 0.34 crore shares aggregating to ₹47.19 crores. The offer for sale portion includes 0.04 crore shares aggregating to ₹5.24 crores. The total number of shares and aggregate amount are 37,72,000 shares aggregating up to ₹52 crores.

Bio Medica Laboratories IPO’s price band is set at ₹132 to ₹139 per share. The lot size for an application is 1,000. The minimum amount of investment required by a retail investor is ₹2,78,000 (2,000 shares) (based on upper price). The minimum lot size investment for HNI is 3 lots (3,000 shares), amounting to ₹4,17,000.

Bio Medica Laboratories engages in the manufacturing of Pharmaceutical Parenteral Formulations. They manufacture a variety of products, including ethical drugs, generic drugs and over-the-counter drugs (OTC) in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. These products address a wide range of medical needs and preferences.

Objectives of Bio Medica Laboratories IPO

• To meet the repayment of the loan.
  
• Enhancement of the company’s existing production capabilities by setting up of a new manufacturing facility at the existing premises.
  
• To meet the general corporate purposes.
  

Industry Outlook

India’s pharmaceutical industry is one of the most significant contributors to the national economy and a key player in the global healthcare landscape. The Indian pharmaceutical sector is evolving from a volume-driven industry to a value-based, innovation-led sector. There is a rising focus on complex generics, specialty drugs, biosimilars, and novel drug delivery systems, particularly in therapeutic areas such as oncology, cardiology, anti-diabetics, and central nervous system (CNS) disorders. Increasing investments in research and development (R&D), combined with strategic global partnerships and acquisitions, are enabling Indian pharmaceutical companies to enter higher-margin and technologically intensive product segments. The Indian pharmaceutical industry is expected to continue its growth trajectory, supported by strong export demand, policy support, expanding therapeutic coverage, and a gradual transition to high-value product portfolios. With continued focus on affordability, accessibility, and innovation, India is well-positioned to play a leading role in advancing global health outcomes in the coming decade.

About Bio Medica Laboratories

Bio Medica Laboratories engages in the manufacturing of Pharmaceutical Parenteral Formulations. They manufacture a variety of products, including ethical drugs, generic drugs and over-the-counter drugs (OTC) in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. These products address a wide range of medical needs and preferences.

They operate on a B2B business model through contract manufacturing and do not deal directly with the end users. The company manufactures formulations for various companies according to their specific requirements and specifications for the type of formulation needed.

Strengths of Bio Medica Laboratories IPO

• Experienced promoters, management, and employees.
• Quality assurance.
• Multi-product capability and diversified product portfolio.
• Established client relationship.
• Low Attrition Rate of employees.

Risks of Bio Medica Laboratories IPO

• Dependency on a limited number of clients for a significant portion of their revenues.
• Any manufacturing or quality control problems may damage their reputation for high-quality products and expose them to litigation or other liabilities, which could adversely affect their financial results.
• Dependency on third-party transportation providers for the supply of raw materials and finished products.
• There are outstanding legal proceedings involving their Promoters and Directors. Any adverse decision in such proceedings may have a material adverse effect on their business, results of operations, and financial condition.
• The occurrence of natural or man-made disasters, hostilities, or civil unrest could adversely impact operations, financial performance, and equity share value.

Note: Industry Peer may be modified for finalization of Issue Price before filing Prospectus with ROC. Sourced from Yearly Audited Financials.

RONW (%) and NAV (Rs. per share) for the peer companies have been calculated as per the yearly audited financials. Notes: Considering the nature and turnover of business of the company, the peers are not strictly comparable. However, the same have been included for broader comparison. The figures for Bio Medica Laboratories are based on the standalone restated results for the period ended March 31, 2025. The figures for the peer group are based on standalone audited results for the period ended March 31, 2025. Current Market Price (CMP) is the closing price of respective scrip as on 8 th May, 2026. PE ratio have been taken as on 8th May 2026.

Anchor Investor Bidding Date: NA

The company in consultation with the BRLM, may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one working day prior to the Issue Opening Date.

Registrar: Skyline Financial Services Private Limited
Book Running Lead Managers: Narnolia Financial Services Limited

Bio Medica Laboratories Business Model

The company earns its revenue through manufacturing Pharmaceutical Parenteral Formulations. They manufacture a variety of products, including ethical drugs, generic drugs, and over-the-counter (OTC) drugs, in the form of injectables such as liquid injections and dry powder injections, which cater to both human and veterinary needs.

Bio Medica Laboratories Growth Trajectory

(Restated Standalone) Bio Medica Laboratories’s Total Income for FY25 was ₹38.325 crores, whereas in FY24 and FY23 it was ₹15.344 crores and ₹16.250 crores, respectively.

The Profit After Tax for FY25 was ₹9.795 crores, whereas in FY24 and FY23 it was ₹2.499 crores and ₹0.333 crores, respectively.

Their EBITDA for FY25 was ₹15.213 crores, whereas in FY24 and FY23 it was ₹5.631 crores and ₹1.699 crores, respectively.

Bio Medica Laboratories Market Position

As of 31 March 2025, the company’s Total Income, Profit After Tax, and EBITDA stood at ₹38.325 crores, ₹9.795 crores, and ₹15.213 crores, respectively.

How to apply for Bio Medica Laboratories IPO?

• Step 1: Log in to your Kotak Neo Demat account to access IPO investments. Next, select the current IPO section.
• Step 2: Specify IPO details. Enter the number of lots and the price you wish to apply for.
• Step 3: Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.
• Step 4: Mandate Notification. Your UPI app will receive a mandate notification to block funds.
• Step 5: Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.